# UROS

## Overview
The UROS gene encodes the enzyme uroporphyrinogen III synthase, a pivotal component of the heme biosynthetic pathway. This enzyme is responsible for catalyzing the conversion of hydroxymethylbilane into uroporphyrinogen III, a crucial precursor in heme synthesis (Tsai1988Human; Aizencang2000Human). Uroporphyrinogen III synthase is characterized by its bilobed structure, with a β-sheet surrounded by α-helices, and functions as a monomer in the cytoplasm (Cunha2007Human; Fortian2011Structural). The UROS gene is located on chromosome 10q25.2-q26.3 and is expressed through both a housekeeping promoter and an erythroid-specific promoter, ensuring appropriate heme production across different tissues (Cunha2007Human; Aizencang2000Human). Mutations in the UROS gene are linked to congenital erythropoietic porphyria, a disorder marked by photosensitivity and hemolytic anemia due to porphyrin accumulation (Blouin2017Missense; Mukhtar2022L237P).

## Structure
Uroporphyrinogen III synthase (UROS) is a crucial enzyme in the heme biosynthetic pathway, characterized by a bilobed structure with two domains connected by a flexible linker. The active site is located in a cleft between these domains, which is essential for its catalytic function (Fortian2011Structural; Mathews2001Crystal). The enzyme's structure includes a β-sheet surrounded by α-helices, contributing to its stability and function (Fortian2011Structural).

The primary structure of UROS is encoded by the UROS gene, located on chromosome 10q25.2-q26.3, and consists of 10 exons (Cunha2007Human). The enzyme functions as a monomer with a molecular weight of approximately 29 kDa (Cunha2007Human). The crystal structure of UROS has been determined at a resolution of 1.85 Å, providing detailed insights into its molecular architecture (Mathews2001Crystal).

NMR-based studies have identified specific residues involved in the active site, located in a major crevice between the two globular domains, which are highly conserved across eukaryotes (Cunha2007Human). The enzyme's flexibility, indicated by domain shifts, is crucial for substrate binding and product release, enhancing its catalytic efficiency (Mathews2001Crystal).

## Function
The UROS gene encodes the enzyme uroporphyrinogen III synthase, which plays a critical role in the heme biosynthetic pathway. This enzyme catalyzes the conversion of hydroxymethylbilane, a linear tetrapyrrole, into uroporphyrinogen III, a cyclic tetrapyrrole, which is a precursor in the synthesis of heme (Tsai1988Human; Aizencang2000Human). Heme is an essential component of hemoglobin, myoglobin, and various cytochromes, which are crucial for oxygen transport and cellular respiration (Cunha2007Human).

In healthy human cells, the UROS gene is expressed through two alternative promoters: a housekeeping promoter and an erythroid-specific promoter. The housekeeping promoter is active in all tissues at low levels, while the erythroid-specific promoter is particularly active during erythroid differentiation, ensuring higher heme production in these cells (Aizencang2000Human). This regulation is vital for maintaining normal heme levels and preventing the accumulation of nonphysiologic isomers that can lead to disorders such as congenital erythropoietic porphyria (Aizencang2000Human). The enzyme functions as a monomer and is active in the cytoplasm, where it facilitates the proper synthesis of heme (Cunha2007Human).

## Clinical Significance
Mutations in the UROS gene, which encodes the enzyme uroporphyrinogen III synthase, are primarily associated with congenital erythropoietic porphyria (CEP), a rare autosomal recessive disorder. This condition is characterized by photosensitivity, hemolytic anemia, and skin lesions due to the accumulation of non-physiological porphyrins (Blouin2017Missense; Mukhtar2022L237P). The severity of CEP correlates with the level of residual enzyme activity. Mutations resulting in absent or very low UROS activity, such as the common p.C73R mutation, are linked to severe clinical symptoms, including non-immune hydrops fetalis and transfusion dependency from birth (Erwin2019Congenital; Warner1992Congenital).

Missense mutations in the UROS gene can lead to protein misfolding and instability, resulting in premature degradation of the enzyme. This instability is a key mechanism contributing to the disease's pathogenesis (Blouin2017Missense). Some mutations, like the L237P substitution, significantly alter the enzyme's structure and function, exacerbating clinical manifestations such as skin abnormalities and anemia (Mukhtar2022L237P). Therapeutic strategies, including the use of proteasome inhibitors, have been suggested to enhance the stability of UROS mutants and reduce porphyrin accumulation (Blouin2017Missense).

## Interactions
Uroporphyrinogen III synthase (UROS) is an enzyme involved in the heme biosynthetic pathway. Despite its crucial role, studies have shown that UROS does not form stable interactions with other enzymes in the heme biosynthetic pathway, such as hydroxymethylbilane synthase (HMB-synthase) and uroporphyrinogen decarboxylase (URO-decarboxylase). NMR-based investigations and in silico docking studies have been conducted to explore potential interactions between UROS and these enzymes. However, these studies did not find evidence of complex formation or stable interactions between UROS and either HMB-synthase or URO-decarboxylase (Cunha2007Human).

The research involved mapping the active site of UROS and examining potential protein-protein interactions using NMR spectroscopy. Minimal perturbations were observed in the NMR spectra of UROS when titrated with HMB-synthase or URO-decarboxylase, suggesting the absence of stable interactions. Specific residues showed slight perturbations, but these were attributed to experimental artifacts rather than genuine interactions (Cunha2007Human). Overall, the studies conclude that UROS does not form stable interactions with other enzymes in the cytosolic heme biosynthetic pathway (Cunha2007Human).


## References


[1. (Aizencang2000Human) Gerardo Aizencang, Constanza Solis, David F. Bishop, Cecilia Warner, and Robert J. Desnick. Human uroporphyrinogen-iii synthase: genomic organization, alternative promoters, and erythroid-specific expression. Genomics, 70(2):223–231, December 2000. URL: http://dx.doi.org/10.1006/GENO.2000.6373, doi:10.1006/geno.2000.6373. This article has 76 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.2000.6373)

[2. (Mathews2001Crystal) M. A.A. Mathews. Crystal structure of human uroporphyrinogen iii synthase. The EMBO Journal, 20(21):5832–5839, November 2001. URL: http://dx.doi.org/10.1093/emboj/20.21.5832, doi:10.1093/emboj/20.21.5832. This article has 74 citations.](https://doi.org/10.1093/emboj/20.21.5832)

[3. (Erwin2019Congenital) Angelika L. Erwin and Robert J. Desnick. Congenital erythropoietic porphyria: recent advances. Molecular Genetics and Metabolism, 128(3):288–297, November 2019. URL: http://dx.doi.org/10.1016/j.ymgme.2018.12.008, doi:10.1016/j.ymgme.2018.12.008. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2018.12.008)

[4. (Cunha2007Human) Luis Cunha, Miklos Kuti, David F. Bishop, Mihaly Mezei, Lei Zeng, Ming‐Ming Zhou, and Robert J. Desnick. Human uroporphyrinogen iii synthase: nmr‐based mapping of the active site. Proteins: Structure, Function, and Bioinformatics, 71(2):855–873, November 2007. URL: http://dx.doi.org/10.1002/prot.21755, doi:10.1002/prot.21755. This article has 17 citations.](https://doi.org/10.1002/prot.21755)

[5. (Blouin2017Missense) Jean-Marc Blouin, Ganeko Bernardo-Seisdedos, Emma Sasso, Julie Esteve, Cécile Ged, Magalie Lalanne, Arantza Sanz-Parra, Pedro Urquiza, Hubert de Verneuil, Oscar Millet, and Emmanuel Richard. Missense uros mutations causing congenital erythropoietic porphyria reduce uros homeostasis that can be rescued by proteasome inhibition. Human Molecular Genetics, 26(8):1565–1576, February 2017. URL: http://dx.doi.org/10.1093/hmg/ddx067, doi:10.1093/hmg/ddx067. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddx067)

[6. (Mukhtar2022L237P) Roshana Mukhtar, Shaheen Shahzad, Sajid Rashid, Maryam Rozi, Madiha Rasheed, Imran Afzal, and Pakeeza Arzoo Shaiq. L237p substitution in the uros gene causes x-linked recessive congenital erythropoietic porphyria in pakistani consanguineous family through altered uroporphyrinogen iii binding. Pakistan Journal of Zoology, 2022. URL: http://dx.doi.org/10.17582/journal.pjz/20200618170629, doi:10.17582/journal.pjz/20200618170629. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.17582/journal.pjz/20200618170629)

[7. (Warner1992Congenital) C A Warner, H W Yoo, A G Roberts, and R J Desnick. Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen iii synthase gene. Journal of Clinical Investigation, 89(2):693–700, February 1992. URL: http://dx.doi.org/10.1172/jci115637, doi:10.1172/jci115637. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci115637)

[8. (Tsai1988Human) S F Tsai, D F Bishop, and R J Desnick. Human uroporphyrinogen iii synthase: molecular cloning, nucleotide sequence, and expression of a full-length cdna. Proceedings of the National Academy of Sciences, 85(19):7049–7053, October 1988. URL: http://dx.doi.org/10.1073/pnas.85.19.7049, doi:10.1073/pnas.85.19.7049. This article has 69 citations.](https://doi.org/10.1073/pnas.85.19.7049)

[9. (Fortian2011Structural) Arola Fortian, David Castaño, Esperanza Gonzalez, Ana Laín, Juan M. Falcon-Perez, and Oscar Millet. Structural, thermodynamic, and mechanistical studies in uroporphyrinogen III synthase:Molecular basis of congenital erythropoietic porphyria, pages 43–74. Elsevier, 2011. URL: http://dx.doi.org/10.1016/b978-0-12-381262-9.00002-1, doi:10.1016/b978-0-12-381262-9.00002-1. This article has 15 citations.](https://doi.org/10.1016/b978-0-12-381262-9.00002-1)